Abstract P260: Determinants of Statin Response: A Secondary Analysis of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Wide variability in LDLC change is observed with statins, yet determinants of statin response are uncertain. Hypotheses: Some markers of inflammation are associated with decreased statin response. Components of metabolic syndrome and older age are associated with better response. Methods: JUPITER (NCT00239681) randomized participants with LDLC<130 mg/dL and hs-CRP≥2 mg/L to rosuvastatin 20 mg/d or placebo. Baseline and 1-year levels of LDLC and a panel of 20 other biomarkers were measured. We defined optimal statin response as ≥50% LDLC reduction; suboptimal response as <50% reduction; and non-response as no change or increase in LDLC. χ 2 , t-tests and ANOVA were used to compare variables across optimal (N=3,801), suboptimal (N=3,235) and non-responders (N=868). Multinomial regression models evaluated associations of determinants of statin response after adjusting for risk factors including compliance. Backward selection identified variables that associated with response. t-distributed Stochastic Neighbor Embedding (t-SNE) suggested predictor clusters for statin response. Results: Compliance was the strongest determinant of statin response (Table). On multivariable analyses, blacks and Hispanics were at higher risk for suboptimal/non-response compared with whites as were greater alcohol use and HbA1c. Higher baseline levels of lipids [lipoprotein(a), apolipoprotein (apo) AI and B], inflammatory biomarkers, and lower branched-chain amino acids associated with decreased statin response (Table). By contrast, determinants of better response included older age, female sex, and higher waist circumference and baseline levels of LDLC, triglycerides, and blood pressure. We observed systematic patterns in t-SNE clustering for statin response by LDLC, LDL particle number, and apo B. Conclusions: This study identified determinants for high-intensity statin response and suggests other pathways of CVD risk beyond those addressed by statin treatment that require further investigation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Abstract P260: Determinants of Statin Response: A Secondary Analysis of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
- Date Crossref
- 03/03/2020
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Brigham and Women's Hospital pays non établi dans la noticeÉtablissement de santé
-
Oluremi N Ajala Brigham and Women's Hosp pays non établi dans la noticeInstitution
-
Olga Demler Brigham and Women's Hosp pays non établi dans la noticeInstitution
-
Yanyan Liu Brigham and Women's Hosp pays non établi dans la noticeInstitution
-
Brigham and Women's Hosp/Harvard Univ pays non établi dans la noticeUniversité ou école supérieure
-
Robert J Glynn Brigham and Women's Hosp pays non établi dans la noticeInstitution
-
Daniel Chasman Brigham and Women's Hosp pays non établi dans la noticeInstitution
-
Samia Mora Brigham and Women's Hosp pays non établi dans la noticeInstitution
Brigham and Women's Hospital, Oluremi N Ajala Brigham and Women's Hosp et Olga Demler Brigham and Women's Hosp, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.